
Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants 2022 Sarah Murphy PMID: 33597216DOI: https://dx.doi.org/10.1136/archdischild-2020-321141 Access Resources Journal ArticleEN About This article comments on a study on how nirsevimab helps reduce RSV-related lung infections and hospital visits in healthy pre-term infants. It highlights the benefits of using a single dose of nirsevimab to prevent these infections. The article is part of ongoing research to find better ways to protect young children from respiratory illnesses caused by RSV, aiming for safer health outcomes for vulnerable infants. Tags Focus Area: Infectious Disease Audience: Physicians Emergency Management Stage: Preparedness (Prevention / Protection) Collection: Nirsevimab Library Keywords: Antibodies, Monoclonal; Hospitalization; Infant; Neonatology; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Therapeutics; Antibodies, Monoclonal, Humanized Institutions: University College Cork More like this Strategies for Improving Vaccine Communication and Uptake 2024 · American Academy of Pediatrics (AAP), University of Colorado, Seattle Children's Hospital, New York Medical College Paediatric Emergency Triage, Assessment and Treatment (ETAT) – Preparedness for Implementation at Primary Care Facilities in Malawi 2021 · Karolinska Institutet, University of Malawi, University College London, Malawi Epidemiology and Intervention Research Unit, Parent and Child Health Initiative Trust, Liverpool School of Tropical Medicine Exploring Parental Perspectives: Maternal RSV Vaccination Versus Infant RSV Monoclonal Antibody 2024 · Children's Health Ireland, University College Dublin The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Access Resources Journal ArticleEN

Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants

2022
Sarah Murphy

PMID: 33597216DOI: https://dx.doi.org/10.1136/archdischild-2020-321141

Access Resources

Journal ArticleEN

About

This article comments on a study on how nirsevimab helps reduce RSV-related lung infections and hospital visits in healthy pre-term infants. It highlights the benefits of using a single dose of nirsevimab to prevent these infections. The article is part of ongoing research to find better ways to protect young children from respiratory illnesses caused by RSV, aiming for safer health outcomes for vulnerable infants.

More like this

Strategies for Improving Vaccine Communication and Uptake 2024 · American Academy of Pediatrics (AAP), University of Colorado, Seattle Children's Hospital, New York Medical College Paediatric Emergency Triage, Assessment and Treatment (ETAT) – Preparedness for Implementation at Primary Care Facilities in Malawi 2021 · Karolinska Institutet, University of Malawi, University College London, Malawi Epidemiology and Intervention Research Unit, Parent and Child Health Initiative Trust, Liverpool School of Tropical Medicine Exploring Parental Perspectives: Maternal RSV Vaccination Versus Infant RSV Monoclonal Antibody 2024 · Children's Health Ireland, University College Dublin

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Access Resources

Journal ArticleEN

Nirsevimab Reduces Medically Attended RSV-Associated Lower Respiratory Tract Infection and Hospitalisations in Healthy Pre-Term Infants

Access Resources

About

Tags

More like this

Access Resources